Eisenberg Or purchased $200K of NRSN
Eisenberg Or (Chief Financial Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market purchase size and price ($0.80) disclosed on 2026-06-17 for a trade dated 2026-06-16.
Market read
Traders may view the insider buy as mildly supportive, but it is unlikely to drive a sustained repricing without accompanying operational catalysts.
What to watch
No 10b5-1 plan is cited, but the filing still lacks context on motivation, timing, and whether other insiders or institutions are changing positions.
Background
This is an SEC Form 4 insider transaction disclosure for NeuroSense Therapeutics Ltd. (NRSN).
Ticker impact
NeuroSense Therapeutics CFO Eisenberg Or filed a Form 4 open-market purchase of 250,000 shares at $0.80 on 2026-06-16.
Likely limited near-term impact; any effect should fade unless followed by additional disclosures or operational news.
The filing is a primary-source insider transaction, but it does not include guidance, trial results, financing, or other company-changing information.
Market effects
Minimal; single-company insider transaction without sector-wide signal.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine liquidity/compensation-related and may not reflect a durable change in fundamentals.
Key entities
- issuerNeuroSense Therapeutics Ltd.
Subject of the Form 4 insider transaction disclosure.
- insiderEisenberg Or
CFO who purchased 250,000 shares open-market at $0.80.
